April 19, 2023 Gamida Cell Announces Pricing of $23 Million Public Offering of Securities View Article
December 12, 2022 Gamida Cell Announces Closing of $25 Million Financing With Highbridge View Article
September 29, 2022 Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting View Article
September 19, 2022 Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies View Article
September 12, 2022 Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting View Article
August 10, 2022 Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 View Article
August 1, 2022 Priority Review of Gamida’s Novel Transplant Therapy Reflects Urgency, Efficacy View Article
June 2, 2022 Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel View Article
June 1, 2022 Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 View Article
